CClinicalTrials.gg
CompletedNCT05767138Updated Mar 14, 2023

STI Knowledge and HPV Vaccine Acceptance in Bamako, Mali in 2012

An observational study in HPV and HPV-Related Cervical Carcinoma, sponsored by Global Alliance to Immunize Against AIDS Vaccine Foundation. Completed. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-14.

Sponsored by Global Alliance to Immunize Against AIDS Vaccine Foundation · Observational

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
301
Ages
12 Years and older
Sex
All
01

Study summary

Although screening for pre-cancerous cervical lesions and human papilloma virus (HPV) vaccination are accepted and effective means to prevent cervical cancer, women in Mali have limited access to these interventions. In addition, cervical cancer prevention by HPV vaccination has been controversial in some settings. To reduce cervical cancer prevalence and increase HPV vaccine uptake, it is important to understand the level of knowledge about cervical cancer screening and practices related to vaccination in at-risk populations. In this study, the level of knowledge about HPV and cervical cancer and attitudes towards vaccination were assessed among 301 participants (male and female, adults and adolescents) in a house-to-house survey in two urban neighborhoods in Bamako, Mali. The survey was combined with a brief educational session on HPV. Prior to the education session, overall knowledge of HPV infection and cervical cancer was very low: only 8% knew that HPV is a sexually transmitted infection (STI). Less than 20% of women had ever consulted a gynecologist and less than 3% had ever had cervical cancer screening. After hearing a description of HPV vaccine, more than 80% would accept HPV vaccination; fathers and husbands were identified as primary decisions makers and local clinics or the home as preferred sites for vaccination. This study provides information on STI knowledge and vaccine acceptance in Bamako, Mali in 2012, prior to the introduction of HPV vaccination.

02

Conditions studied

  • HPV
  • HPV-Related Cervical Carcinoma

Keywords

  • Mali
  • Bamako
  • Survey
03

In context

Lead sponsor

Global Alliance to Immunize Against AIDS Vaccine Foundation is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Participants were recruited between May and June 2011 in Mèkin-Sikoro and Djikoroni, two peri-urban communities of Bamako that have been site for previous population surveys. Adolescents were eligible if aged 12-17 years and living in the household, and if a guardian was available to provide consent. Adults (male and female) were eligible if aged >18 years and living in the household. A total of 301 participants participated (150 living in households in Djikoroni, 151 living in Me´kin-Sikoro)

Inclusion criteria

  • 12-17 years of age, with guardian consent
  • 18 years or older
  • Male or Female
  • Living in Mèkin-Sikoro and Djikoroni

Exclusion criteria

Exclusion Criteria:

  • 12-17 years of age, without guardian consent
  • \<12 years of age
  • Living outside Mèkin-Sikoro and Djikoroni
05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
301 participants (actual)
Patient registry
No

Groups and cohorts

  • Bamako Participants

    301 male and female participants. Teenagers and adults. Living in two urban regions of Bamako.

    Behavioral: HPV Vaccine Acceptance Survey

Interventions

  • BehavioralHPV Vaccine Acceptance Survey
06

What researchers measure

Primary outcomes

  1. Participants' acceptance of the vaccine

    Number of participants willing to be vaccinated against HPV and their vaccination preferences after educational sessions

    Time frame: immediately after the intervention

Secondary outcomes

  1. Knowledge of STIs, HPV, and Cervical Cancer

    Knowledge Question asked before and after educational session

    Time frame: immediately after the intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

  • Protocol, analysis plan and consent form · Mar 18, 2011

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05767138
Lead sponsor
Global Alliance to Immunize Against AIDS Vaccine Foundation
Collaborators
Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
Mar 2011
Primary completion
May 2011
Completion
Jun 2011
Last update
Mar 14, 2023

Study contacts

Anne De Groot, MD
principal investigator · GAIA Vaccine Foundation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Global Alliance to Immunize Against AIDS Vaccine Foundation

Start the discussion